» Articles » PMID: 27604320

Neuronal Leucine-rich Repeat 1 Negatively Regulates Anaplastic Lymphoma Kinase in Neuroblastoma

Overview
Journal Sci Rep
Specialty Science
Date 2016 Sep 9
PMID 27604320
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In neuroblastoma (NB), one of the most common paediatric solid tumours, activation of anaplastic lymphoma kinase (ALK) is often associated with poor outcomes. Although genetic studies have identified copy number alteration and nonsynonymous mutations of ALK, the regulatory mechanism of ALK signalling at protein levels is largely elusive. Neuronal leucine-rich repeat 1 (NLRR1) is a type 1 transmembrane protein that is highly expressed in unfavourable NB and potentially influences receptor tyrosine kinase signalling. Here, we showed that NLRR1 and ALK exhibited a mutually exclusive expression pattern in primary NB tissues by immunohistochemistry. Moreover, dorsal root ganglia of Nlrr1+/+ and Nlrr1-/- mice displayed the opposite expression patterns of Nlrr1 and Alk. Of interest, NLRR1 physically interacted with ALK in vitro through its extracellular region. Notably, the NLRR1 ectodomain impaired ALK phosphorylation and proliferation of ALK-mutated NB cells. A newly identified cleavage of the NLRR1 ectodomain also supported NLRR1-mediated ALK signal regulation in trans. Thus, we conclude that NLRR1 appears to be an extracellular negative regulator of ALK signalling in NB and neuronal development. Our findings may be beneficial to comprehend NB heterogeneity and to develop a novel therapy against unfavourable NB.

Citing Articles

The expression of LRRN4 was correlated with the progression and prognosis of colon adenocarcinoma (COAD) patients.

Zhang Y, Xie J, Liu D, Zhu S, Zhang S Genet Mol Biol. 2021; 45(1):e20210138.

PMID: 34919118 PMC: 8679243. DOI: 10.1590/1678-4685-GMB-2021-0138.


NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.

Takatori A, Hossain M, Ogura A, Akter J, Nakamura Y, Nakagawara A Front Oncol. 2021; 11:669667.

PMID: 34277416 PMC: 8279747. DOI: 10.3389/fonc.2021.669667.


EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.

Li Z, Takenobu H, Setyawati A, Akita N, Haruta M, Satoh S Oncogene. 2018; 37(20):2714-2727.

PMID: 29507419 PMC: 5955864. DOI: 10.1038/s41388-018-0133-3.


The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.

Lu J, Guan S, Zhao Y, Yu Y, Woodfield S, Zhang H Cancer Lett. 2017; 400:61-68.

PMID: 28455243 PMC: 5502736. DOI: 10.1016/j.canlet.2017.04.022.

References
1.
Bresler S, Wood A, Haglund E, Courtright J, Belcastro L, Plegaria J . Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011; 3(108):108ra114. PMC: 3319004. DOI: 10.1126/scitranslmed.3002950. View

2.
Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

3.
Zhu S, Lee J, Guo F, Shin J, Perez-Atayde A, Kutok J . Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell. 2012; 21(3):362-73. PMC: 3315700. DOI: 10.1016/j.ccr.2012.02.010. View

4.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout E . Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res. 2010; 16(17):4353-62. DOI: 10.1158/1078-0432.CCR-09-2660. View

5.
Linardou H, Dahabreh I, Bafaloukos D, Kosmidis P, Murray S . Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009; 6(6):352-66. DOI: 10.1038/nrclinonc.2009.62. View